SEARCHCOHORTophthalmology, oncology

cohort·ophthalmology, oncology, retina, clinical trial, research methods·PMC10044715

A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival

BMC Cancer · 7 authors, 2 centres

AI SUMMARY

FIDELITY 100%

POPULATION83 patients diagnosed with posterior uveal melanoma between 1996 and 2000.

INTERVENTIONA serum protein signature test (serUM-Px) based on levels of leptin and osteopontin measured from a peripheral blood sample obtained at diagnosis.

COMPARISONPatients were stratified into low, intermediate, and high metastatic risk categories. Survival outcomes were compared across these categories.

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This study developed and validated a serum protein test (serUM-Px) using leptin and osteopontin levels from a single blood draw at diagnosis to stratify uveal melanoma patients into low, intermediate, and high metastatic risk categories. In the validation cohort, higher risk category was associated with significantly shorter metastasis-free and overall survival.

Full summary

621 CHARS

The study developed a prognostic test, serUM-Px, for uveal melanoma using serum protein profiling. From an initial panel of 84 proteins, low leptin and high osteopontin were selected as biomarkers. In the validation cohort, increasing serUM-Px risk category was associated with shorter metastasis-free and overall survival, and higher cumulative incidence of melanoma-related mortality. The test was an independent predictor of metastasis in a multivariate Cox regression, with a hazard ratio of 3.2 (95% CI 1.5–6.9). The findings suggest serUM-Px is a minimally invasive alternative for risk stratification at diagnosis.

PICO

PPOPULATION

83 patients diagnosed with posterior uveal melanoma between 1996 and 2000.

IINTERVENTION

A serum protein signature test (serUM-Px) based on levels of leptin and osteopontin measured from a peripheral blood sample obtained at diagnosis.

OOUTCOME

Metastasis-free survival, overall survival, and cumulative incidence of uveal melanoma-related mortality.

STUDY TYPE

cohort

SPECIALTY

ophthalmology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10044715

A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival

BMC Cancer

READ THE FULL PAPER

ABSTRACT

Abstract Purpose To develop a prognostic test based on a single blood sample obtained at the time of uveal melanoma diagnosis. Methods 83 patients diagnosed with posterior uveal melanoma between 1996 and 2000 were included. Peripheral serum samples were obtained at diagnosis and kept at -80 °C until this analysis. Protein profiling of 84 cancer-related proteins was used to screen for potential biomarkers and a prognostic test that stratifies patients into metastatic risk categories was developed (serUM-Px) in a training cohort and then tested in a validation cohort. Results Low serum leptin levels and high osteopontin levels were found to identify patients with poor prognosis and were therefore selected for inclusion in the final test. In the validation cohort, patient sex and American Joint Committee on Cancer stages were similarly distributed between the low, intermediate, and high metastatic risk categories. With increasing metastatic risk category, patients had shorter metastasis-free- and overall survival, as well as greater cumulative incidence of uveal melanoma-related mortality in competing risk analysis ( P = 0.007, 0.018 and 0.029, respectively). In multivariate Cox regression, serUM-Px was an independent predictor of metastasis with tumor size and patient sex as covariates (hazard ratio 3.2, 95% CI 1.5–6.9). Conclusions A prognostic test based on a single peripheral venous blood sample at the time of uveal melanoma diagnosis stratifies patients into low, intermediate, and high metastatic risk categories. Prospective validation will facilitate its clinical utility. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-023-10757-x. Keywords: Uveal melanoma, Choroidal melanoma, Liquid biopsy, Serum sample, Proteome, Prognosis, Survival, Metastasis, serUM-Px

CITATION EXPORT

Christina Herrspiegel, Flavia Plastino, Emma Lardner et al.. A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival. BMC Cancer. (2023). https://doi.org/10.1186/s12885-023-10757-x

AUTHORS

7 · 2 CENTRES

Christina Herrspiegel, Flavia Plastino, Emma Lardner, Stefan Seregard, Pete A Williams, Helder André, Gustav Stålhammar

1St. Erik Eye Hospital, Eugeniavägen 12, 4078, Stockholm, 171 64 Sweden
2Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet, Tomtebodavägen 18A, Stockholm, 171 77 Sweden